$VBIVQ
VBI Vaccines Inc/BC Stock $vbivq

$vbivq Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000149315223007351 Filed on March 13, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$485.0K	$293.0K	$1.082M
YoY Change	284.92%	261.73%	71.47%
Cost Of Revenue	$3.559M	$3.328M	$11.28M
YoY Change	29.23%	2.12%	4.7%
Gross Profit	-$3.074M	-$3.035M	-$10.19M
YoY Change	16.97%	-4.5%	0.54%
Gross Profit Margin	-633.81%	-1035.84%	-942.14%
Selling, General & Admin	$13.28M	$15.89M	$56.12M
YoY Change	21.54%	26.8%	46.39%
% of Gross Profit
Research & Development	$3.151M	$2.518M	$15.51M
YoY Change	33.4%	-51.26%	-20.72%
% of Gross Profit
Depreciation & Amortization	$508.0K	$520.0K	$2.061M
YoY Change	7.4%	10.87%	12.32%
% of Gross Profit
Operating Expenses	$19.99M	$18.40M	$82.90M
YoY Change	50.42%	4.01%	43.2%
Operating Profit	-$19.51M	-$21.44M	-$81.82M
YoY Change	22.54%	2.72%	20.27%
Interest Expense	$1.429M	$298.0K	$4.007M
YoY Change	-126.79%	-85.73%	-332.83%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$27.75M	-$21.14M	-$113.3M
YoY Change	30.57%	12.55%	62.43%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$27.75M	-$21.14M	-$113.3M
YoY Change	30.57%	12.55%	62.43%
Net Earnings / Revenue	-5721.86%	-7215.36%	-10471.63%
Basic Earnings Per Share	-$3.22		-$0.44
Diluted Earnings Per Share	-$3.22	-$0.08	-$0.44
COMMON SHARES
Basic Shares Outstanding	258.3M shares	258.3M shares	258.3M shares
Diluted Shares Outstanding	8.609M shares		8.609M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$40.39M	$62.63M	$62.63M
YoY Change	-60.14%	-48.54%	-48.54%
Cash & Equivalents	$40.39M	$62.63M
Short-Term Investments
Other Short-Term Assets	$1.976M	$6.059M	$4.335M
YoY Change	-51.59%	66.78%	-5.1%
Inventory	$6.768M	$6.599M	$6.599M
Prepaid Expenses	$2.419M	$2.309M
Receivables	$281.0K	$94.00K	$94.00K
Other Receivables	$1.203M	$4.033M	$4.033M
Total Short-Term Assets	$51.84M	$77.69M	$77.69M
YoY Change	-53.86%	-40.37%	-40.37%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.69M	$12.25M	$15.57M
YoY Change	-20.43%	11.02%	8.26%
Goodwill	$2.132M	$2.127M
YoY Change		-5.93%
Intangibles	$58.50M	$58.35M
YoY Change		-6.03%
Long-Term Investments
YoY Change
Other Assets	$1.311M	$1.355M	$1.355M
YoY Change	-9.34%	7.63%	7.63%
Total Long-Term Assets	$76.63M	$77.40M	$77.40M
YoY Change	-6.16%	-3.25%	-3.25%
TOTAL ASSETS
Total Short-Term Assets	$51.84M	$77.69M	$77.69M
Total Long-Term Assets	$76.63M	$77.40M	$77.40M
Total Assets	$128.5M	$155.1M	$155.1M
YoY Change	-33.79%	-26.25%	-26.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.837M	$12.97M	$12.97M
YoY Change	150.5%	203.11%	203.11%
Accrued Expenses	$12.18M	$14.82M	$14.82M
YoY Change	-16.98%	-8.15%	-8.15%
Deferred Revenue	$649.0K	$409.0K
YoY Change		-22.24%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$29.57M	$36.94M	$36.94M
YoY Change	-13.0%	13.37%	13.37%
LONG-TERM LIABILITIES
Long-Term Debt	$49.36M	$48.89M	$48.89M
YoY Change	99.12%	71.89%	71.89%
Other Long-Term Liabilities	$4.507M	$5.093M	$5.093M
YoY Change	-20.41%	-5.11%	-5.11%
Total Long-Term Liabilities	$53.87M	$53.98M	$53.98M
YoY Change	76.89%	59.67%	59.67%
TOTAL LIABILITIES
Total Short-Term Liabilities	$29.57M	$36.94M	$36.94M
Total Long-Term Liabilities	$53.87M	$53.98M	$53.98M
Total Liabilities	$83.44M	$90.92M	$90.92M
YoY Change	29.48%	36.94%	36.94%
SHAREHOLDERS EQUITY
Retained Earnings	-$517.4M	-$489.6M
YoY Change		29.4%
Common Stock	$534.3M	$532.3M
YoY Change		20.37%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$45.02M	$64.16M	$64.16M
YoY Change
Total Liabilities & Shareholders Equity	$128.5M	$155.1M	$155.1M
YoY Change	-33.79%	-26.25%	-26.25%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$27.75M	-$21.14M	-$113.3M
YoY Change	30.57%	12.55%	62.43%
Depreciation, Depletion And Amortization	$508.0K	$520.0K	$2.061M
YoY Change	7.4%	10.87%	12.32%
Cash From Operating Activities	-$21.66M	-$19.05M	-$73.70M
YoY Change	8.69%	2.86%	84.66%
INVESTING ACTIVITIES
Capital Expenditures	$534.0K	$1.452M	$4.344M
YoY Change	-203.69%	-338.03%	-317.74%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$534.0K	-$1.452M	-$4.344M
YoY Change	3.69%	138.03%	-118.76%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		0.000	$19.45M
YoY Change		-100.0%	-56.09%
NET CHANGE
Cash From Operating Activities	-$21.66M	-19.05M	-$73.70M
Cash From Investing Activities	-$534.0K	-1.452M	-$4.344M
Cash From Financing Activities		0.000	$19.45M
Net Change In Cash	-$22.24M	-20.50M	-$59.07M
YoY Change	8.86%	26.27%	-314.46%
FREE CASH FLOW
Cash From Operating Activities	-$21.66M	-$19.05M	-$73.70M
Capital Expenditures	$534.0K	$1.452M	$4.344M
Free Cash Flow	-$22.19M	-$20.50M	-$78.04M
YoY Change	14.32%	14.48%	105.84%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0000764195
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	VBIV	Stock Issued During Period Value Common Shares Issued Upon Cashless Exercise Of Warrants StockIssuedDuringPeriodValueCommonSharesIssuedUponCashlessExerciseOfWarrants		usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments		usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2021	VBIV	Non Cash Adjustments For Prior Periods From Adoption NonCashAdjustmentsForPriorPeriodsFromAdoption		usd
CY2022	VBIV	Warrants Modification In Connection With Debt Amendment WarrantsModificationInConnectionWithDebtAmendment		usd
CY2021	VBIV	Warrants Issued In Connection With Financing Transactions WarrantsIssuedInConnectionWithFinancingTransactions		usd
CY2022	us-gaap	Stock Issued1 StockIssued1		usd
CY2022	VBIV	Common Shares Issued Upon Conversion Of Longterm Debt CommonSharesIssuedUponConversionOfLongtermDebt		usd
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods		usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent		usd
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent		usd
CY2021	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized		usd
CY2021	VBIV	Contract With Customer Liability Currency Translation ContractWithCustomerLiabilityCurrencyTranslation		usd
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch		usd
CY2021	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-37769
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	A1
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	160 Second Street
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Floor 3
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	77396000	usd
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02142
CY2022	dei	City Area Code CityAreaCode	(617)
CY2022	dei	Local Phone Number LocalPhoneNumber	830-3031
CY2022	dei	Security12b Title Security12bTitle	Common Shares, no par value per share
CY2022	dei	Trading Symbol TradingSymbol	VBIV
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	154978074	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	258257494	shares
CY2022	dei	Auditor Firm AuditorFirmId	274
CY2022	dei	Auditor Name AuditorName	EISNERAMPER LLP
CY2022	dei	Auditor Location AuditorLocation	Iselin, New Jersey
CY2022Q4	us-gaap	Cash Cash	62629000	usd
CY2021Q4	us-gaap	Cash Cash	121694000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	94000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	6599000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	2576000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2309000	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2373000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	6059000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3633000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	77690000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	130284000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1355000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1259000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12253000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11037000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3316000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3344000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	58345000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	62091000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	2127000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	2261000	usd
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	79992000	usd
CY2022Q4	us-gaap	Assets Assets	155086000	usd
CY2021Q4	us-gaap	Assets Assets	210276000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	12973000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4280000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	22588000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	26941000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	409000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	526000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	972000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	839000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	36942000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	32586000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2365000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2516000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	48888000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	28441000	usd
CY2022Q4	us-gaap	Accrued Participation Liabilities Due In Next Operating Cycle AccruedParticipationLiabilitiesDueInNextOperatingCycle	524000	usd
CY2021Q4	us-gaap	Accrued Participation Liabilities Due In Next Operating Cycle AccruedParticipationLiabilitiesDueInNextOperatingCycle	574000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	2204000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	2277000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	53981000	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	33808000	usd
CY2022Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2021Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	258257494	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	258257494	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	258250273	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	258250273	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	442312000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	442235000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	90020000	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	81583000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	21440000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1565000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-489609000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-378371000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	64163000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	143882000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	155086000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	210276000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1082000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	631000	usd
CY2022	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	11276000	usd
CY2021	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	10770000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15506000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19558000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	56120000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	38335000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	82902000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	68663000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-81820000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-68032000	usd
CY2022	us-gaap	Interest Expense InterestExpense	4007000	usd
CY2021	us-gaap	Interest Expense InterestExpense	4732000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-27476000	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	3011000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-113303000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-69753000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-113303000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-69753000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	23005000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2830000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-90298000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-72583000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	258257296	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	254947202	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	171705000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	32176000	usd
CY2021	VBIV	Stock Issued During Period Value Common Shares Issued Upon Exercise Of Warrants StockIssuedDuringPeriodValueCommonSharesIssuedUponExerciseOfWarrants	85000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4000	usd
CY2021	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	2000000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	867000	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	9628000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-69753000	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-2830000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	143882000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	143882000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	681000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	12000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1550000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	9698000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-113303000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	23005000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	64163000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	64163000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-113303000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-69753000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2061000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1835000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	9698000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	9628000	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1707000	usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2999000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-172000	usd
CY2022	VBIV	Inventory Reserve InventoryReserve	1186000	usd
CY2021	VBIV	Inventory Reserve InventoryReserve	174000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-27445000	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	496000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	87000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-69000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5690000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	513000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-18000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	787000	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	2738000	usd
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-5558000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	173000	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	584000	usd
CY2022	VBIV	Increase Decrease In Operating Right Of Use Assets IncreaseDecreaseInOperatingRightOfUseAssets	-1357000	usd
CY2021	VBIV	Increase Decrease In Operating Right Of Use Assets IncreaseDecreaseInOperatingRightOfUseAssets	-1071000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	8893000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	356000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	16000	usd
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-328000	usd
CY2022	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-2910000	usd
CY2021	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	11931000	usd
CY2022	VBIV	Operating Lease Proceeds And Payments OperatingLeaseProceedsAndPayments	1347000	usd
CY2021	VBIV	Operating Lease Proceeds And Payments OperatingLeaseProceedsAndPayments	1068000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-73695000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-39908000	usd
CY2021	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	25151000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4344000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1995000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4344000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	23156000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	33293000	usd
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1067000	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	85000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	12000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4000	usd
CY2022	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	20000000	usd
CY2021	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	12000000	usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	563000	usd
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	22000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	19449000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	44293000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-475000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	328000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-59065000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	27869000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	121694000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	93825000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	62629000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	121694000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	3231000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	2039000	usd
CY2022	VBIV	Non Cash Adjustments For Prior Periods From Adoption NonCashAdjustmentsForPriorPeriodsFromAdoption	681000	usd
CY2021	VBIV	Warrants Modification In Connection With Debt Amendment WarrantsModificationInConnectionWithDebtAmendment	867000	usd
CY2022	VBIV	Warrants Issued In Connection With Financing Transactions WarrantsIssuedInConnectionWithFinancingTransactions	1550000	usd
CY2021	us-gaap	Stock Issued1 StockIssued1	4298000	usd
CY2021	VBIV	Common Shares Issued Upon Conversion Of Longterm Debt CommonSharesIssuedUponConversionOfLongtermDebt	2000000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	406000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	185000	usd
CY2022	VBIV	Share Issuance Costs Included In Accounts Payable And Other Current Liabilities ShareIssuanceCostsIncludedInAccountsPayableAndOtherCurrentLiabilities	67000	usd
CY2021	VBIV	Share Issuance Costs Included In Accounts Payable And Other Current Liabilities ShareIssuanceCostsIncludedInAccountsPayableAndOtherCurrentLiabilities	50000	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80C_eus-gaap--NatureOfOperations_z64KmU898bS1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1. <span id="xdx_826_zM0Uu7s5QyT6">NATURE OF BUSINESS AND CONTINUATION OF BUSINESS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate Overview</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">VBI Vaccines Inc. (the “Company” or “VBI”) was incorporated under the laws of British Columbia, Canada on <span id="xdx_903_edei--EntityIncorporationDateOfIncorporation_dd_c20220101__20221231_zxtPYvd5XtCl" title="Entity incorporation, date of incorporation">April 9, 1965</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company and its wholly-owned subsidiaries, VBI Vaccines (Delaware) Inc., a Delaware corporation (“VBI DE”); VBI DE’s wholly-owned subsidiary, Variation Biotechnologies (US), Inc., a Delaware corporation (“VBI US”); Variation Biotechnologies, Inc. a Canadian company and the wholly-owned subsidiary of VBI US (“VBI Cda”); SciVac Ltd. an Israeli company (“SciVac”); SciVac Hong Kong Limited (“SciVac HK”) and VBI Vaccines B.V a Netherlands company (“VBI BV”), are collectively referred to as the “Company”, “we”, “us”, “our”, or “VBI”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s registered office is located at Suite 1700, Park Place, 666 Burrard Street, Vancouver, BC V6C 2X8 with its principal office located at 160 Second Street, Floor 3, Cambridge, MA 02142. In addition, the Company has manufacturing facilities located in Rehovot, Israel and research facilities located in Ottawa, Ontario, Canada.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal Operations</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">VBI Vaccines Inc. (“VBI”) is a commercial stage biopharmaceutical company driven by immunology in the pursuit of prevention and treatment of disease. Through its innovative approach to virus-like particles (“VLPs”), including a proprietary enveloped VLP (“eVLP”) platform technology, VBI develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. VBI is committed to targeting and overcoming significant infectious diseases, including hepatitis B (“HBV”), COVID-19 and coronaviruses, and cytomegalovirus (“CMV”), as well as aggressive cancers including glioblastoma (“GBM”). VBI is headquartered in Cambridge, Massachusetts, with research operations in Ottawa, Canada, and a research and manufacturing site in Rehovot, Israel.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The COVID-19 pandemic has materially negatively affected the global economy, and the ongoing effects of the COVID-19 pandemic, including but not limited to, supply chain issues, global shortages of supplies, materials and products, volatile market conditions and rising global inflation, continue to do so. As a result of the COVID-19 pandemic, our business and results of operations were adversely affected and, as the ongoing effects of the COVID-19 pandemic continue to impact the global economy, these effects may continue to adversely affect our business and results of operations. The extent to which these effects will continue to impact our business will depend on future developments, which are highly uncertain and cannot be predicted. We do not yet know the full extent of potential delays or impacts on our business, our clinical studies, our research programs, the recoverability of our assets, and our manufacturing; however, the effects of the COVID-19 pandemic may continue to disrupt or delay our business operations, including with respect to efforts relating to potential business development transactions, and it could continue to disrupt the marketplace which could have an adverse effect on our operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity and Going Concern</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company faces a number of risks, including but not limited to, uncertainties regarding the success of the development and commercialization of its products, demand and market acceptance of the Company’s products, and reliance on major customers. The Company anticipates that it will continue to incur significant operating costs and losses in connection with the development and commercialization of its products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has an accumulated deficit of $<span id="xdx_90C_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3n3_di_c20221231_zNOTE5mtsxpe">489,609 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and cash of $<span id="xdx_908_eus-gaap--Cash_iI_pn3n3_c20221231_zRyK4Ck22Dod">62,629</span> as of December 31, 2022. Cash outflows from operating activities were $<span id="xdx_908_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_di_c20220101__20221231_zxoUrTRDRAsj">73,695 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the year-ended December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company will require significant additional funds to conduct clinical and non-clinical trials, commercially launch our products, and achieve regulatory approvals. Additional financing may be obtained from the issuance of equity securities, the issuance of additional debt, government or non-governmental organization grants or subsidies, and/or revenues from potential business development transactions, if any. There is no assurance the Company will manage to obtain these sources of financing, if required. The above conditions raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from this uncertainty.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--DescriptionOnVaccineDevelopment_pn3n3_c20220101__20221231_zaO0ROWL5Ht9" title="Description on vaccine development">On March 9, 2021, the Company and the Coalition for Epidemic Preparedness Innovations (“CEPI”) announced a partnership (“CEPI Funding Agreement”) to develop eVLP vaccine candidates against SARS-COV-2 variants, including the Beta variant, also known as the B.1.351 variant and 501Y.V2, first identified in South Africa. CEPI agreed to provide up to $33,018 to support the advancement of VBI-2905, a monovalent eVLP candidate expressing the pre-fusion form of the spike protein from the Beta variant, through Phase I clinical development</span>. This funding will also support preclinical expansion of additional multivalent vaccine candidates designed to evaluate the potential breadth of our eVLP technology. The preclinical expansion is intended to develop clinic-ready vaccine candidates capable of addressing emerging variants. See more information on the CEPI Funding Agreement in Note 14.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 17, 2021, the Company entered into the First Amendment to the Loan and Guaranty Agreement and Affirmation of Pledge and Security Agreement (the “First Amendment”) with K2 HealthVentures LLC (“K2HV”) and any other lender from time-to-time party thereto. See Note 10 for more details.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2021, the Company issued <span id="xdx_902_ecustom--CommonSharesIssuedUponCashlessExerciseOfWarrantsShares_pid_c20210601__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PerceptiveCreditHoldingsMember_z3pcmyAVQ2Re" title="Number of common stock issued">646,257</span> common shares to Perceptive Credit Holdings, LP and PCOF EQ AIV, LP (related parties), upon exercise of <span id="xdx_908_ecustom--CashLessExerciseOfWarrants_pid_c20210601__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PerceptiveCreditHoldingsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zG5qkmxcvcIg" title="Cashless exercise of warrants">2,068,824</span> warrants on a cashless “net exercise” basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 3, 2021, the Company entered into a second Open Market Sale Agreement<sup>SM</sup> with Jefferies LLC (“Jefferies”) to act as the Company’s sales agent and/or principal, for the issuance and sale of up to an additional $<span id="xdx_902_ecustom--OpenMarketSaleAgreementSales_pn3n3_c20210903__20220826__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_zUOxwKKPjUK2" title="Open market sale agreement sales cost">125,000</span> of the Company’s common shares from time to time in an at-the-market public offering, which the Company could choose to use when no shares remain available for issuance under the first ATM Program. On July 31, 2020, the Company entered into an Open Market Sale Agreement with Jefferies, pursuant to which the Company may offer and sell its common shares having an aggregate price of up to $<span id="xdx_907_ecustom--OpenMarketSaleAgreementSales_pn3n3_c20200731__20220826__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_zkhdJ7Rso2xb" title="Open market sale agreement sales cost">125,000</span> from time to time through Jefferies, acting as agent or principal (the “first ATM Program”). Common shares were offered pursuant to a sales agreement prospectus included in the Company’s automatic shelf registration on Form S-3 filed with the United States Securities and Exchange Commission (“SEC”) on July 31, 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 1, 2022, we received a letter from the Listings Qualifications Department of Nasdaq indicating that, based upon the closing bid price of our common shares for the 30 consecutive business day period between May 18, 2022, through June 30, 2022, we did not meet the minimum bid price of $<span id="xdx_906_eus-gaap--SharePrice_iI_pid_c20220702__srt--RangeAxis__srt--MinimumMember_zA7BX6t9xyM9" title="Bid price">1.00</span> per share required for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we were provided an initial period of 180 calendar days, or until December 28, 2022, to regain compliance. On December 29, 2022, we were granted an additional 180-day grace period to regain compliance with the Minimum Bid Price Requirement. To regain compliance and qualify for continued listing on Nasdaq, the closing bid price of our common shares must be at least $1.00 for a minimum of 10 consecutive business days during the additional 180-day grace period, which will end on June 26, 2023. Nasdaq’s determination was based on our meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on Nasdaq, with the exception of the Minimum Bid Price Requirement, and our written notice of our intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. We have not regained compliance as of the date of this filing, and if we fail to regain compliance during this grace period, our common shares will be subject to delisting by Nasdaq, which could seriously decrease or eliminate the value of an investment in our common shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 26, 2022, the Company 1) filed a registration statement for a base prospectus which covers the offering, issuance and sale of up to $<span id="xdx_908_ecustom--RemainingShareValueRelatedToBaseProspectus_pn3n3_c20220825__20220826__us-gaap--TypeOfArrangementAxis__custom--BaseProspectusMember__srt--RangeAxis__srt--MaximumMember_z6VA0Wad8fHl" title="Issuance and sale of common shares">300,000</span> of common shares, warrants, units and/or subscription rights; and 2) entered into an Open Market Sale Agreement with Jefferies, pursuant to which the Company may offer and sell its common shares having an aggregate price of up to $<span id="xdx_90E_ecustom--RemainingShareValueRelatedToATMProgram_pn3n3_c20220825__20220826__us-gaap--TypeOfArrangementAxis__custom--CurrentATMProgramMember__srt--RangeAxis__srt--MaximumMember_zStR1lCOZnQ9" title="Share value remaining, available for sale">125,000</span> from time to time through Jefferies, acting as agent or principal (the “ATM Program”). The ATM Program replaces Open Market Sale Agreements previously entered into with Jefferies on July 31, 2020, and September 3, 2021, pursuant to each of which we could offer and sell our common shares having an aggregate price of up to $<span id="xdx_905_ecustom--OriginalShareValueRelatedToAtmProgram_pn3n3_c20200701__20220826__us-gaap--TypeOfArrangementAxis__custom--FirstATMProgramMember_zu5pQBYtE0S8" title="Original share value related to ATM Program"><span id="xdx_90F_ecustom--OriginalShareValueRelatedToAtmProgram_pn3n3_c20210903__20220826__us-gaap--TypeOfArrangementAxis__custom--SecondATMProgramMember_zJYMWbI4FWGh" title="Original share value related to ATM Program">125,000</span></span> from time to time, through ATM equity offering programs. Both ATM programs were terminated, effective as of August 26, 2022. Prior to termination, $<span id="xdx_909_ecustom--RemainingShareValueRelatedToATMProgram_pn3n3_c20220825__20220826__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__us-gaap--AwardTypeAxis__custom--FirstAtTheMarketMember_zwZ4FHn1yF15" title="Share value remaining, available for sale">27,022</span> of our common shares remained available for sale pursuant to the first ATM program, and $<span id="xdx_903_ecustom--RemainingShareValueRelatedToATMProgram_pn3n3_c20210903__20220826__us-gaap--TypeOfArrangementAxis__custom--FirstATMProgramMember_zVvssHOEHEL5" title="Share value remaining, available for sale">125,000</span> of our common shares remained available for sale pursuant to the second ATM program. Neither ATM program was utilized in 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In September 2022, the Company refinanced its existing term loan facility with K2HV to increase the amount of term loans available to $<span id="xdx_90E_ecustom--IncreaseInAmountOfTermLoansAvailable_iI_pn3n3_c20220930__dei--LegalEntityAxis__custom--K2HealthventuresLLCMember_zDlpQCPwVs8d" title="Increase amount of term loans available">100,000</span> among other items. See Note 10 for more details. The refinanced long-term debt has a maturity date of September 14, 2026.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	1965-04-09
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-489609000	usd
CY2022Q4	us-gaap	Cash Cash	62629000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-73695000	usd
CY2022	VBIV	Description On Vaccine Development DescriptionOnVaccineDevelopment	On March 9, 2021, the Company and the Coalition for Epidemic Preparedness Innovations (“CEPI”) announced a partnership (“CEPI Funding Agreement”) to develop eVLP vaccine candidates against SARS-COV-2 variants, including the Beta variant, also known as the B.1.351 variant and 501Y.V2, first identified in South Africa. CEPI agreed to provide up to $33,018 to support the advancement of VBI-2905, a monovalent eVLP candidate expressing the pre-fusion form of the spike protein from the Beta variant, through Phase I clinical development
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_845_eus-gaap--UseOfEstimates_zZPlkE1yVWlc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zLHmMaFQ5v7d">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual amounts could differ from the estimates made. We continually evaluate estimates used in the preparation of the consolidated financial statements for reasonableness. Appropriate adjustments, if any, to the estimates used are made prospectively based upon such periodic evaluation. The significant areas of estimation include revenue recognition, determining the deferred tax valuation allowance, estimating accrued research and development expenses, the inputs in determining the fair value of the in-process research and development (“IPR&D”) and goodwill as part of the annual impairment analysis and the inputs in determining the fair value of equity-based awards and warrants issued. Actual results may differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84A_eus-gaap--ConcentrationRiskCreditRisk_zrdEyqAsXQZg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zkR6rD4uL7ta">Concentration of Credit Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash and accounts receivable. We place our cash primarily in commercial checking accounts. Commercial bank balances may from time to time exceed federal insurance limits.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has not experienced any losses in cash and accounts receivable for the years ended December 31, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 10, 2023, Silicon Valley Bank (“SVB”) was closed by the California Department of Financial Protection and Innovation, and the Federal Deposit Insurance Corporation (“FDIC”) was appointed as receiver. The Company has deposit accounts at SVB. The standard deposit insurance amount is up to $<span id="xdx_902_ecustom--StandardDepositInsurance_iI_c20230310__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zeEBZJRf1p8k" title="Standard deposit insurance">250</span> per depositor, per insured bank, for each account ownership category. As of March 10, 2023, the Company had approximately $<span id="xdx_900_eus-gaap--DepositAssets_iI_c20230310__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zSw8bgHYoaRg">1,200</span> in deposit accounts at SVB. On March 12, 2023, the U.S. Treasury, Federal Reserve, and FDIC announced that SVB depositors will have access to all of their money starting March 13, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3633000	usd
CY2022	VBIV	Schedule Of Estimated Useful Lives Of Property And Equipment ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipment	<p id="xdx_89E_ecustom--ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipment_zs8ZkCMTEZo6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The assets are depreciated by the straight-line method over the estimated useful lives of the related assets as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B6_zubM6WEO6chh" style="display: none; font-family: Times New Roman, Times, Serif">SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; width: 62%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and office equipment</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zUuH08h3QQs7" title="Property, Plant and Equipment, Useful Life">5</span>-<span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zjuZ47bLIK4b" title="Property, Plant and Equipment, Useful Life">14</span></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery and equipment</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_z6zJPjCGL0T2" title="Property, Plant and Equipment, Useful Life">3</span>-<span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_zZ05TonmQyGe" title="Property, Plant and Equipment, Useful Life">7</span></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computers</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zPg5lxSCyLu8" title="Property, plant and equipment, useful life">2</span>-<span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_z0xv7rHjecy6" title="Property, plant and equipment, useful life">3</span></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zAFMxcwC4jEd" title="Property, plant and equipment, useful lives">shorter of useful life or the term of the lease</span></span></td></tr> </table>
CY2022	VBIV	Annual Impairment Test Description AnnualImpairmentTestDescription	Some of the more significant estimates and assumptions inherent in the estimate of the fair value of IPR&D assets including: 1) the amount and timing of costs to develop the IPR&D into viable products; 2) the amount and timing of future cash inflows; 3) the discount rate; and 4) the probability of technical and regulatory success. The discount rate used was 12% and the cumulative probability of technical and regulatory success to achieve approval to market the products ranged from approximately 10% to 17%
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	20234000	usd
CY2022Q4	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	56510000	usd
CY2021Q4	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	30406000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7981000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12253000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	6059000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	893000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1869000	usd
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	645000	usd
CY2022Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	3837000	usd
CY2021Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	1931000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	6599000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	2576000	usd
CY2022	VBIV	Inventory Reserve InventoryReserve	1186000	usd
CY2021	VBIV	Inventory Reserve InventoryReserve	174000	usd
CY2022Q4	us-gaap	Government Contract Receivable GovernmentContractReceivable	4033000	usd
CY2021Q4	us-gaap	Government Contract Receivable GovernmentContractReceivable	1438000	usd
CY2022Q4	VBIV	Other Current Assets OtherCurrentAssets	2026000	usd
CY2021Q4	VBIV	Other Current Assets OtherCurrentAssets	2195000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	15996000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4959000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11037000	usd
CY2022	us-gaap	Depreciation Depreciation	2009000	usd
CY2021	us-gaap	Depreciation Depreciation	1768000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	62169000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-669000	usd
CY2022	VBIV	Finite Lived Intangible Assets Cumulative Impairment Charge FiniteLivedIntangibleAssetsCumulativeImpairmentCharge	-300000	usd
CY2022	VBIV	Finite Lived Intangible Assets Cumulative Currency Translation FiniteLivedIntangibleAssetsCumulativeCurrencyTranslation	-2855000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	58345000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	62169000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-660000	usd
CY2021	VBIV	Finite Lived Intangible Assets Cumulative Impairment Charge FiniteLivedIntangibleAssetsCumulativeImpairmentCharge	-300000	usd
CY2021	VBIV	Finite Lived Intangible Assets Cumulative Currency Translation FiniteLivedIntangibleAssetsCumulativeCurrencyTranslation	882000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	62091000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	52000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	67000	usd
CY2022	us-gaap	Finite Lived Intangible Assets Foreign Currency Translation Gain Loss FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss	3690000	usd
CY2021	us-gaap	Finite Lived Intangible Assets Foreign Currency Translation Gain Loss FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss	2000	usd
CY2022Q4	us-gaap	Goodwill Gross GoodwillGross	8714000	usd
CY2022Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	6292000	usd
CY2022Q4	VBIV	Goodwill Cumulative Currency Translation GoodwillCumulativeCurrencyTranslation	-295000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	2127000	usd
CY2021Q4	us-gaap	Goodwill Gross GoodwillGross	8714000	usd
CY2021Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	6292000	usd
CY2021Q4	VBIV	Goodwill Cumulative Currency Translation GoodwillCumulativeCurrencyTranslation	-161000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	2261000	usd
CY2022	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	134000	usd
CY2021	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	0	usd
CY2022Q4	VBIV	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	6561000	usd
CY2021Q4	VBIV	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	8196000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3250000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2294000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4036000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4805000	usd
CY2022Q4	VBIV	Deferred Funding Current DeferredFundingCurrent	6966000	usd
CY2021Q4	VBIV	Deferred Funding Current DeferredFundingCurrent	10183000	usd
CY2022Q4	VBIV	Other Current Liabilities OtherCurrentLiabilities	1775000	usd
CY2021Q4	VBIV	Other Current Liabilities OtherCurrentLiabilities	1463000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	22588000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	26941000	usd
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	32571391	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21328040	shares
CY2021	us-gaap	Severance Costs1 SeveranceCosts1	16000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	48888000	usd
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	28441000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	48888000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	28441000	usd
CY2022	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	55699000	usd
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	3515000	usd
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	2105000	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1707000	usd
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2999000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-172000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	1387000	usd
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	372000	usd
CY2022	us-gaap	Interest Expense InterestExpense	4007000	usd
CY2021	us-gaap	Interest Expense InterestExpense	4732000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	442000	usd
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	352000	usd
CY2021	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.0833	pure
CY2022	us-gaap	Severance Costs1 SeveranceCosts1	5000	usd
CY2021Q4	VBIV	Deferred Tax Assets Deferred Financing Costs DeferredTaxAssetsDeferredFinancingCosts	1779000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	98580000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	87169000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	22844620	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.38
CY2022Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	22841970	shares
CY2022	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P7Y2M19D
CY2022Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	15563719	shares
CY2022Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	2.51
CY2022	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P6Y6M14D
CY2021	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P6Y6M
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2022Q4	VBIV	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Vested ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueVested	0	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.9323	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.9687	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0175	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0059	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M29D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y10M6D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.13
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.40
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	9698000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	9628000	usd
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	8950000	usd
CY2022	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y5M4D
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1082000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	631000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	98580000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	87169000	usd
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	2613000	usd
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	3104000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2803000	usd
CY2022	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	66000	usd
CY2022	VBIV	Contract With Customer Liability Currency Translation ContractWithCustomerLiabilityCurrencyTranslation	124000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2613000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	409000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	2204000	usd
CY2018Q4	VBIV	Additional Potential Regulatory And Sales Milestone Payments AdditionalPotentialRegulatoryAndSalesMilestonePayments	117500000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2613000	usd
CY2022	VBIV	Description Of Vaccine Development DescriptionOfVaccineDevelopment	On March 9, 2021, the Company and CEPI announced the CEPI Funding Agreement, to develop eVLP vaccine candidates against SARS-COV-2 variants, including the Beta variant, also known as the B.1.351 variant and as 501Y.V2, first identified in South Africa. CEPI agreed to provide up to $33,018 to support the advancement of VBI-2905, a monovalent eVLP candidate expressing the pre-fusion form of the spike protein from the Beta variant strain, through Phase I clinical development
CY2022	VBIV	Funding Received FundingReceived	964000	usd
CY2020Q3	VBIV	Contribution Agreement Description ContributionAgreementDescription	(i) 75% of VBI Cda’s costs incurred in respect of the Project, subject to certain eligibility limitations as set forth in the Contribution Agreement and (ii) CAD $56 million from the SIF to support the development of our coronavirus vaccine program, VBI-2900, though Phase II clinical studies (the “Project”).
CY2021Q4	VBIV	Deferred Tax Assets Debt Obligation DeferredTaxAssetsDebtObligation	-1757000	usd
CY2022Q4	VBIV	Deferred Tax Assets Deferred Financing Costs DeferredTaxAssetsDeferredFinancingCosts	1201000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-113303000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-69753000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-113303000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-69753000	usd
CY2022	VBIV	Income Tax Reconciliation Expected Benefit Of Income Tax IncomeTaxReconciliationExpectedBenefitOfIncomeTax	-30025000	usd
CY2021	VBIV	Income Tax Reconciliation Expected Benefit Of Income Tax IncomeTaxReconciliationExpectedBenefitOfIncomeTax	-18485000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-386000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	1970000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	12562000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	19099000	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	2771000	usd
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	1313000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	2362000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	2387000	usd
CY2022	VBIV	Income Tax Reconciliation Of Foreign Exchange On Unrecognized Temporary Differences IncomeTaxReconciliationOfForeignExchangeOnUnrecognizedTemporaryDifferences	10814000	usd
CY2021	VBIV	Income Tax Reconciliation Of Foreign Exchange On Unrecognized Temporary Differences IncomeTaxReconciliationOfForeignExchangeOnUnrecognizedTemporaryDifferences	-4574000	usd
CY2022	VBIV	Income Tax Reconciliation Repatriation Of Foreign Earning IncomeTaxReconciliationRepatriationOfForeignEarning	-308000	usd
CY2021	VBIV	Income Tax Reconciliation Repatriation Of Foreign Earning IncomeTaxReconciliationRepatriationOfForeignEarning	480000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	240000	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-220000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	98147000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	86397000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	13995000	usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	14102000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1072000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1050000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	2253000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	1996000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	-15461000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	-16454000	usd
CY2022Q4	VBIV	Allowable Capital Losses AllowableCapitalLosses	56000	usd
CY2021Q4	VBIV	Allowable Capital Losses AllowableCapitalLosses	56000	usd
CY2022Q4	VBIV	Deferred Tax Assets Debt Obligation DeferredTaxAssetsDebtObligation	-2683000	usd
CY2022Q4	VBIV	Net Operating Loss Carryforwards NetOperatingLossCarryforwards	409363000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	409363000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	1865000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	1463000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y11M15D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.13	pure
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1327000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1228000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	719000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	619000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	168000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4061000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	724000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3337000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	972000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2365000	usd
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1082000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	631000	usd
CY2022Q4	VBIV	Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	15569000	usd
CY2021Q4	VBIV	Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	14381000	usd

Files In Submission

Name	View Source	Status
0001493152-23-007351-index-headers.html	Edgar Link	pending
0001493152-23-007351-index.html	Edgar Link	pending
0001493152-23-007351.txt	Edgar Link	pending
0001493152-23-007351-xbrl.zip	Edgar Link	pending
ex10-48.htm	Edgar Link	pending
ex10-48_001.jpg	Edgar Link	pending
ex10-49.htm	Edgar Link	pending
ex10-50.htm	Edgar Link	pending
ex10-51.htm	Edgar Link	pending
ex10-51_001.jpg	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vbiv-20221231.xsd	Edgar Link	pending
vbiv-20221231_cal.xml	Edgar Link	unprocessable
vbiv-20221231_def.xml	Edgar Link	unprocessable
vbiv-20221231_lab.xml	Edgar Link	unprocessable
vbiv-20221231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VBIVQ
VBI Vaccines Inc/BC Stock $vbivq

2023 Q1 Form 10-K Financial Statement

#000149315223007351 Filed on March 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VBIVQ VBI Vaccines Inc/BC Stock $vbivq

2023 Q1 Form 10-K Financial Statement

#000149315223007351 Filed on March 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VBIVQ
VBI Vaccines Inc/BC Stock $vbivq